News

For people with myasthenia gravis (MG) and other chronic diseases, it’s important to be proactive in learning how to best manage the condition and connect with others in the disease community. “The first thing I really need to let you know is that you’re the only person who can…

Maintaining a hopeful outlook is a vital part of managing myasthenia gravis (MG). Hope can help improve a person’ quality of life and may even modulate disease activity, according to Jeffrey Rosenfeld, MD, PhD, director of the Center for Restorative Neurology at Loma Linda University Health, who discussed the…

Treatment with rozanolixizumab — an investigational therapy being developed by UCB for generalized myasthenia gravis (gMG) — worked in a clinical trial to ease symptom severity for a subset of patients who were positive for muscle specific kinase (MuSK) antibodies. That’s according to analyses from the Phase…

The use of Ultomiris (ravulizumab) led to stronger reductions in generalized myasthenia gravis (gMG) symptoms for people who had been living with the disease for no more than two years, new analyses from the CHAMPION MG trial indicated. “Overall, our analysis suggests that treatment of gMG with [Ultomiris]…

Ultomiris (ravulizumab) treatment led to sustained reductions in generalized myasthenia gravis (gMG) symptom severity and acute clinical worsening events for more than a year, according to new analyses from the CHAMPION MG clinical trial and its open-label extension (OLE). The analyses were presented at the Muscular Dystrophy Association’s…

Vyvgart (efgartigimod) eased symptoms of generalized myasthenia gravis (gMG) in patients regardless of their disease length, treatment history, or acetylcholine receptor (AChR) antibody status, according to two new analyses from the ADAPT clinical trial and its open-label extension, ADAPT+. These findings serve to reinforce “the efficacy of efgartigimod…

Vyvgart (efgartigimod) won approval in the U.K. as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who are positive for acetylcholine receptor (AChR)-targeting antibodies. “We are pleased to announce this latest regulatory approval of Vyvgart, another exciting advancement toward our vision of making our…

High levels of anti-acetylcholine receptor (AChR) antibodies — the most common self-reactive antibodies known to drive myasthenia gravis (MG) — in people with ocular MG are linked to greater odds of developing generalized MG, according to a recent study. People with ocular MG who had high anti-AChR antibody…

Repetitive nerve stimulation (RNS), a standard tool used to diagnose myasthenia gravis (MG), was unable to predict disease severity over the long term, or other MG outcomes, among people with the neuromuscular condition, a study found. While there was a correlation between RNS results and disease severity at symptom…

Batoclimab (HBM9161) eased the symptoms of generalized myasthenia gravis (gMG) and their impact on daily function, hitting the main and secondary goals of a Phase 3 clinical trial in China. No new side effects arose during the trial (NCT05039190) and the experimental therapy, which is being developed by…